RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept
RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept
加拿大皇家銀行在1比12的反向股票拆分後將Avalo Therapeutics的目標股價從24美元下調至21美元；跑贏大盤，投機風險保持不變
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊